Myovant Sciences Debt 2025

Myovant Sciences Aktienanalyse

What does Myovant Sciences do?

Myovant Sciences Ltd. is a biotech company based in London that specializes in medications for women and men in various therapy areas. The company was founded in 2016 through the collaboration of Takeda Pharmaceutical and Roivant Sciences Ltd. After going public in 2016, Myovant is now listed on the NYSE. Myovant Sciences focuses on medications for the treatment of reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company is involved in research and development of new therapy options and currently has a pipeline of 5 projects focusing on the following indications: - Symptomatic uterine fibroids - Endometriosis - Prostate cancer - Reproductive disorders in women - Reproductive disorders in men A fibroid is a growth in the tissue of the uterus that often occurs in women of reproductive age and becomes symptomatic. Endometriosis is a chronic, painful condition where tissue that normally lines the uterus grows outside of it. Myovant can also offer treatment options for reproductive disorders in men. The founders of Myovant Sciences aim to improve patient care, especially for rare diseases that are often under-researched and lack effective treatment options. The company focuses on innovative technologies and customized solutions to differentiate themselves from other companies. This includes a focus on targeted therapy options tailored to specific patient groups. Myovant has embraced the motto "Don't become MVP (Most Valuable Player), become MVP - Medical Value Provider." The company works closely with clinics, universities, research institutions, and other companies in the industry to leverage the latest scientific developments and use them for the development of medical solutions for the market. Myovant offers a wide range of products, with a main focus on medications for women and men with severe reproductive system, hormone, and urinary tract disorders in aging individuals. An example of a product is Elagolix, which was developed in collaboration with Abbvie Inc. for the treatment of endometriosis-related pain in women. Myovant Sciences Ltd. is an innovative company with an ambitious goal of developing medications for patients suffering from reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company conducts research and development of products for specific indications in order to offer targeted therapy options for patients. Myovant works closely with numerous partners to develop innovative solutions for patients. Myovant Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Myovant Sciences's Debt Structure

Myovant Sciences's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Myovant Sciences's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Myovant Sciences’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Myovant Sciences’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Myovant Sciences stock

What is the debt of Myovant Sciences this year?

Myovant Sciences has a debt level of -48 USD this year.

What was the debt of Myovant Sciences compared to the previous year?

The debt of Myovant Sciences has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in Myovant Sciences?

High debt can pose a risk for investors of Myovant Sciences, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Myovant Sciences?

Low debt means that Myovant Sciences has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Myovant Sciences affect the company?

An increase in debt of Myovant Sciences can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Myovant Sciences affect the company?

A reduction in debt of Myovant Sciences can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Myovant Sciences?

Some factors that can influence the debt of Myovant Sciences include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Myovant Sciences so important for investors?

The debts of Myovant Sciences are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Myovant Sciences take to change the debt?

To change the debt, Myovant Sciences can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Myovant Sciences pay?

Over the past 12 months, Myovant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Myovant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Myovant Sciences?

The current dividend yield of Myovant Sciences is .

When does Myovant Sciences pay dividends?

Myovant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Myovant Sciences?

Myovant Sciences paid dividends every year for the past 0 years.

What is the dividend of Myovant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Myovant Sciences located?

Myovant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Myovant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Myovant Sciences from 7/11/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/11/2025.

When did Myovant Sciences pay the last dividend?

The last dividend was paid out on 7/11/2025.

What was the dividend of Myovant Sciences in the year 2024?

In the year 2024, Myovant Sciences distributed 0 USD as dividends.

In which currency does Myovant Sciences pay out the dividend?

The dividends of Myovant Sciences are distributed in USD.